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ABSTRACT
According to the Nutritional Prevention of Cancer (NPC) trial, a selenized yeast 
supplement containing selenium, 200 mcg/day, decreased the incidence of total 
cancer, cancers of the prostate, colon and lung, and cancer mortality. The active agent 
in the selenized yeast supplement was assumed to be selenomethionine (SEMET), 
although the supplement had not been well speciated. The SELECT study, largely 
motivated by the NPC trial, enrolling nearly 40 times as many subjects, showed 
unequivocally that selenium 200 mcg/day, with selenium in the form of SEMET, does 
not protect selenium-replete men against prostate or other major cancer. The agent 
tested by SELECT, pure SEMET, could have been different from the selenized yeast 
tested in NPC. One of the selenium forms suspected of having chemopreventive effects, 
and which may have been present in the NPC agent, is methyl selenocysteine (MSC). 
This study, with 29 selenium-replete patients enrolled in a randomized, double-blind 
trial, compared the multiple-dose toxicity, pharmacokinetics and pharmacodynamics 
of MSC and SEMET.   Patients were on trial for 84 days. No toxicity was observed. 
Although SEMET supplementation increased blood selenium concentration more 
than MSC did, neither form had a more than minimal impact on the two major 
selenoproteins: selenoprotein P(SEPP1) and glutathione peroxidase(GPX).
INTRODUCTION
Selenium (Se) is an essential nutrient [1]; lower 
Se levels in toenails and blood have been associated in 
ecological and individual-based epidemiologic studies 
with increased risk of cancer and a number of other chronic 
diseases [2–4]. Nonetheless, experimental evidence that 
selenium supplementation decreases the risk of cancer 
or of other chronic diseases is mixed at best. The NPC 
trial, which randomized 1312 patients with a history 
of nonmelanoma skin cancer to 200 mcg selenium per 
day in selenized yeast or to a yeast placebo, gave rise to 
great optimism regarding selenium’s chemopreventive 
properties. NPC patients were treated and followed 
for an average of 7.4 years, and patients randomized to 
selenium experienced significantly decreased total cancer 
incidence, mainly of the lung, colon and prostate; they 
also experienced significantly decreased total cancer 
incidence and mortality [5–7]. The association of selenium 
supplementation with decreased risk was especially marked 
for prostate cancer [6] and the strongest association of 
selenium supplementation with decreased risk was noticed 
among subjects in the lowest tertile of baseline plasma 
selenium. An important caveat for the NPC findings is that 
these endpoints were secondary to the primary endpoint: 
non melanoma skin cancer recurrence. Assignment to 
supplementation did not decrease, but slightly increased, 
non melanoma skin cancer recurrence [8].
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In a trial testing selenium as a lung cancer 
prevention agent, Karp and colleagues randomized over 
1500 patients with resected non-small cell lung cancer to 
selenized yeast or to placebo; those patients were chosen 
to represent a very high risk group. The trial, designed for 
a 4-year treatment period, was halted after futility analysis 
showed that the endpoints of second primary tumors 
and progression-free survival were unlikely to differ in 
selenium and placebo groups [9] The larger SELECT 
study, conducted among 35,533 average-risk men, closed 
early, with subjects followed for an average of 5.5 years. 
The study was discontinued after the data safety and 
monitoring committee concluded from futility analysis 
that there was virtually no possibility that selenium 
supplementation would be found to decrease the risk of 
any of the primary endpoints [10]. SWOG 9917, a small 
study testing whether selenium supplements diminish 
the progression of high grade prostatic intraepithelial 
neoplasia to prostate cancer, showed that selenium 
supplements had no such effect [11]. 
Comparisons between the NPC, Karp, SELECT 
and SWOG 9917 studies bring to light two differences 
of potential importance. First, different forms of Se were 
used in the trials: SEMET in SELECT and SWOG 9917, 
selenized yeast in NPC and the Karp trial [5, 8, 9, 11]. A 
post-trial analysis of the selenium in the analyzed yeast of 
the NPC showed highly variable amounts of SEMET [12] 
and several other compounds. A comparison of selenized 
yeast and SEMET showed that these two agents have 
approximately equal effects on the generation of two key 
selenoproteins: selenoprotein P (SEPP1) and glutathione 
peroxidase (GPX) [13]. A second difference among these 
trials is that some of the subjects in the NPC trial—
especially those in the lowest baseline plasma selenium 
tertile— were close to being— or were— selenium 
deficient, while few to none of those in Karp’s lung cancer 
trial, SELECT or SWOG 9917 were [5,6,9,10]. Although 
the impact of selenium supplementation in NPC appeared to 
be affected by baseline selenium status, selenium’s impact 
in SELECT and SWOG 9917 appeared not to be [14]. 
The mechanisms by which selenium might inhibit 
carcinogenesis or otherwise serve as a chemopreventive 
agent are not known. It has been hypothesized that a key 
selenium mechanism involves protection against oxidative 
stress [15–22] . Those with inadequate selenium stores 
would, according to this hypothesis, be at increased risk. 
SEMET is absorbed via methionine transporters and 
becomes part of the methionine pool [13]. The first steps 
in methionine metabolism are a methionine cycle and 
transsulfuration; a fraction of methionine molecules in the 
mammal are SEMET, so that transsulfuration generates 
some selenocysteine. Selenocysteine can be converted to 
selenide, which is critical to synthesis of selenoproteins 
[23, 24]. Both SEMET and MSC can be transformed to 
methylselenol, which in cell lines exerts chemopreventive 
activity [23, 25–27]. Methylselenol, with redox activity 
and possible effects on signaling in cell lines, has been 
proposed as a key metabolite in cancer prevention [28], 
although it may, in vivo, simply represent the first step on 
an excretory pathway [29]. As selenium and sulfur share 
a number of physiologic characteristics, SEMET can be 
incorporated into proteins at methionine positions and, 
thereby, stored as selenomethionine in albumin. Given 
methionine’s importance in proteins, the displacement 
by selenium of a functionally important sulfur atom 
has the potential to alter the function of protein-based 
cellular processes. With continued ingestion, the pool 
of SEMET accumulates within the body; plasma levels 
tend to increase until toxicity disturbs metabolism [13]. 
Approximately 35% of a single 200 mcg dose of Se given 
as MSC is excreted in urine or feces within 12 days [25]; 
by contrast, only 15% of the Se in SEMET will have been 
excreted within that time span [26]. Approximately equal 
amounts of selenium in MSC are recovered from urine 
and feces [25], while twice as much selenium given as 
SEMET is recovered from urine as from feces. Additional 
amounts are excreted in breath [29]. Unidentified selenium 
forms may have been present in the NPC yeast [12]. One 
of these, possibly MSC, may have been at least partly 
responsible for its apparent chemopreventive effects [30].
Whether any chemopreventive impact of either 
SEMET or MSC would stem strictly from their impact 
on these two selenoproteins—or on other selenoproteins—
can be argued. Chemopreventive action could result from 
metabolites of these compounds’ inhibiting of histone 
deacetylase [31, 32].
 A single-dose MSC study over 48 hours showed 
that Se doses of 400, 800, and 1200 mcg significantly 
elevated plasma levels of selenium; there was little 
difference in the dose elevation generated by the 400 and 
800 mcg doses [30]. The study did not examine changes 
in plasma selenoproteins. 
 The impact of MSC as opposed to SEMET on 
selenoproteins would help to illuminate the likely 
physiological importance of these two selenium forms, 
as well as their possible roles in cancer. It is important, 
though, that the impact of either agent could result from 
mechanisms other than the formation of selenoproteins 
[32–34]. 
In cell line models, MSC contributes more directly 
than SEMET to methylselenol [27, 28, 35], which can 
be demethylated to yield selenide [36, 37] or further 
methylated to yield dimethyl selenide. Dimethyl selenide 
is excreted in the breath or, if not released into breath, 
methylated again to yield trimethyl selenonium and 
excreted in the urine. It is pertinent to selenium-based 
chemoprevention to evaluate SEMET and MSC within a 
single experimental design. The goal of this report was 
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first to test the toxicity of high doses of MSC and SEMET, 
then to compare and contrast their pharmacokinetics and 
pharmodynamics in selenium-replete subjects.
RESULTS
Between 12/20/2011 and 2/13/2014, 29 patients 
were enrolled in the study. The characteristics of subjects 
are shown in Table 1. Two extra subjects were accidentally 
assigned to the 400 mcg dose; their data are included in 
the results. Variations in the age, pretreatment plasma 
Se, height, weight and BMI of subjects were within 
expectations based on chance; none of these demographic 
or baseline values varied to a statistically significant 
degree. The ECOG performance status score ranged from 
0, meaning that the subject is fully active, to 1, meaning 
that the subject is restricted in daily activity but able to 
complete light, sedentary tasks. The mean and median 
ECOG scores were one, in keeping with the eligibility 
requirements. 
The primary endpoints were toxicity and changes 
in biomarkers. In total, 4 adverse events were reported 
in the 29 eligible subjects who began the study: a grade 
two hyperbilirubinemia in a placebo participant judged 
as possibly related to treatment; a grade 2 hyperglycemia 
in a placebo participant judged as unrelated to treatment 
; and two severe adverse events— diagnosis of bladder 
cancer in an MSC participant, judged unlikely related 
to treatment; and a stroke diagnosed in an MSC patient, 
judged unlikely related to treatment. These findings 
revealed no association between assignment to MSC, 
SEMET or placebo and the occurrence of adverse or 
severe adverse events. The 4 patients with adverse or 
serious adverse events were excluded from the analyses. 
Table 2 shows predose values of subjects, by agent 
and by dose, on days 1, 28 and 84. The overall mean 
baseline plasma selenium concentration of participants 
on day 1was 108 mcg/L (not shown). Variability in day 1 
predose plasma selenium and SEPP 1 concentrations, and 
urinary selenium/creatinine ratios was modest enough to 
be attributed to chance. By days 28 and 84, the Se levels of 
those receiving 400 and 800 mcg of selenium as SEMET 
had nearly doubled; the differences from baseline were 
statistically significant. The day 28 and 84 Se levels of 
those assigned the 400 mcg dose of MSC had increased by 
a statistically significant degree; this was not seen in those 
assigned the 800 mcg dose of MSC. Among those assigned 
SEMET, values increased appreciably by day 28; by day 
84, plasma concentrations had more than doubled for 
those receiving the 400 mcg dose, while the level among 
those receiving the 800 mcg dose had nearly tripled. The 
only statistically significant change in plasma SEPP1 
levels observed was on day 28 for subjects assigned to the 
800 mcg dose of MSC. By day 84, plasma SEPP1 of these 
subjects had dropped back, close to baseline. 
There was statistically significant variance among 
the treatment groups in predose, day 1 and day 28 
GPX, Nevertheless, although there were changes in 
GPX activity, none of these was statistically significant. 
Changes in the ratio of urinary selenium to creatinine take 
into account a number of extraneous factors, including 
muscle mass. The pre-dose ratio of urine selenium to 
creatinine among subjects assigned to MSC or to SEMET, 
whether 400 or 800 mcg Se, increased significantly by day 
84. The differences are noteworthy, with the day 84 levels 
3 to 5 times baseline. 
Table 3 summarizes the day 1 and day 84 kinetics 
of plasma Se: maximum concentration (Cmax); time to 
maximum concentration (Tmax); and area under the curve 
(AUC). The day 1 Cmax values of each subject did not 
differ significantly. By day 84, levels of subjects assigned 
the 400 mcg doses of MSC and SEMET, and those of 
subjects assigned the 800 mcg dose of SEMET were 
significantly increased. Variance and changes in the Tmax 
values of subjects receiving the two species and doses of 
selenium on days 1 and 84 were within the bounds of what 
might be expected by chance. The AUC of subjects on day 
1 did not vary substantially by Se dose; by day 84, for both 
the 400 and 800 mcg doses of SEMET, and the 400 mcg 
dose of MSC, AUC had increased significantly. 
Table 4 shows SEPP1 kinetics. Cmax, Tmax 
and AUC for SEPP1 were similar, with no noteworthy 
variation induced by agent or dose at any point in time. 
The one statistically significant increase was in Cmax for 
participants receiving the 400 mcg dose of MSC. It was 
not seen in the 400 mcg dose of SEMET or the 800 mcg 
dose of SEMET or MSC. Neither Tmax nor AUC changed 
significantly by day 84.
Table 5 summarizes pharmacokinetic changes in 
Gpx activity. None of the changes –in Cmax, Tmax or 
AUC—was statistically significant. 
Table 6 provides detail on 12-hour selenium 
excretion: the total amount of selenium excreted in urine 
within 12 hours, and the ratio of selenium excreted to the 
dose assigned. There was no noteworthy or statistically 
significant change in the amounts of selenium excreted 
among placebo patients. Among those assigned to 
selenium, the amounts excreted in urine were substantial. 
The ratio of selenium excreted within 12 hours to the 
amount in the dose to which the subject was assigned 
ranged on day 1 from .15 to .26. By day 84, the ratio was 
even higher, ranging from .26 to .42. 
DISCUSSION
These data represent the only direct comparison 
to date of MSC and SEMET as selenium species 
administered to humans. The goal of this study was to 
pursue the possibility that MSC might exhibit differential 
pharmacokinetic and/or pharmacodynamic effects as 
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compared to those of SEMET. A substantial difference, 
particularly in pharmacodynamics, might have suggested 
a difference in anticarcinogenic potential. The results 
indicate that, in selenium-replete subjects, SEMET 
treatment results in higher blood selenium concentrations 
than does MSC. Further, the higher day 84 Cmax and AUC 
values with SEMET, compared to those at day 1, suggest 
accumulation of selenium with time. Together these 
findings confirm strong differences in pharmacokinetics 
of SEMET as opposed to MSC. However, this study 
failed to identify any meaningful pharmacodynamic 
differences between SEMET and MSC. Importantly, no 
Table 1: Participants, phase 1 study of 12-Week treatment by selenomethionine or 
methylselenocysteine in adult males
Treatment Group
Agent Placebo Methyl Selenocysteine Selenomethionine
Dose   400 mcg 800 mcg  400 mcg 800 mcg
N 3 7 5 5 5
MEAN ± SD
Age (years) 49.3 ± 8 55.6 ± 10 55.9 ± 11 62.2 ± 7 58.9 ± 10
Height (m) 1.8 ± 0.8 1.8 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 1.9 ± 0.0
Weight (kg) 91 ± 20 93 ± 13 90 ± 10 88.9 ± 17 95 ± 10
BMI 28 ± 2 29.2 ± 3 27.7 ± 3 28.6 ± 5 27.4 ± 2.
ECOG Performance Status Frequency (%)
'Fully Active' 2 (67) 6 (86) 4 (80) 5 (100) 4 (80)
Table 2: Predose selenium and metabolites by agent and by day or study
Treatment Group
Agent Placebo Methyl Selenocysteine Selenomethionine
Dose   400 mcg 800 mcg  400 mcg 800 mcg
N 3 7 5 5 5
Plasma Se concentration (mcg/L)
Day 1 106 ± 12 108 ± 15 116 ± 14 105 ± 8 104 ± 14
Day 28 101 ± 7 129 ± 231 128 ± 13 209 ± 361 244 ± 431
Day 84 95 ± 131 123 ± 131 120 ± 12 230 ± 221 291 ± 471
Plasma Selenoprotein P concentration (mg/L)
Day 1 8.0 ± 12 6.9 ± 10 7.5 ± 16 7.0 ± 12 7.5 ± 4
Day 28 7.5 ± 6 7.6 ± 20 8.5 ± 131 6.6 ± 15 7.9 ± 12
Day 84 7.7 ± 17 7.3 ± 12 7.8 ± 12 6.5 ± 12 7.7 ± 10
Plasma Glutathione Peroxidase activity (Unit/L)
Day 1 112 ± 33 112 ± 11 148 ± 34 104 ± 13 132 ± 30
Day 28 115 ± 35 121 ± 16 150 ± 20 125 ± 17 167 ± 52
Day 84 113 ± 45 122 ± 24 185 ± 62 121 ± 16 154 ± 36
Urine Se /Creatinine ratio (ng Se/mg creatine)
Day 1 58.4 ± 55 30.6 ± 10 31.6 ± 9 44.0 ± 12 27.4 ± 11
Day 28 41.3 ± 21 81.4 ± 16 124 ± 29 113 ± 30 142 ± 33
Day 84 61.9 ± 45 90.91 ± 18 124 ± 21 138 ± 391 131 ± 571
1Difference from Day 1 p <.05 (paired t test).
*Mean ± SD.
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pharmacodynamic effects were observed with either 
SEMET or MSC, when compared to control. It is critical, 
though, that the measures of pharmacodynamics were 
limited to changes in two selenoproteins. 
Preclinical data indicated that selenium is important 
in protection against oxidative stress [15–22, 28, 36, 
38–40]. Selenium deficiency has also been associated 
with increased cancer risk [25, 26, 41, 42]. Whether 
supplementation of those who are selenium deficient 
decreases vulnerability to oxidative stress is not well 
known; whether an agent that protects against oxidative 
stress would protect against carcinogenesis is not known. 
The Karp trial [9] SELECT [10] and SWOG 9917 [11] 
document that selenium supplementation by SEMET offers 
no protection among men who are selenium replete [10].
The NPC study found selenium supplementation 
to be associated with protection only among subjects 
in the lowest baseline tertile of plasma selenium [6, 7]. 
Although an analysis of a subset of SELECT participants 
found no modification of supplementation effects by 
Table 4: Selenoprotein P pharmacokinetics
Treatment Group
Agent Placebo Methyl Selenocysteine Selenomethionine
Dose   400 mcg 800 mcg  400 mcg 800 mcg
N 3 7 5 5 5
Plasma Selenoprotein P Cmax (mg/L)
Day 1 8.37 ± 1 7.84 ± 1 8.62 ± 2 7.56 ± 1 8.38 ± 1
Day 84 8.83 ± 2 8.53 ± 11 8.14 ± 1 7.44 ± 2 8.14 ± 1
Plasma Selenoprotein P Tmax (hr)
Day 1 3.00 ± 4 9.14 ± 7 10.8 ± 8 6.10 ± 10 2.80 ± 3
Day 84 5.00 ± 4 5.07 ± 5 5.80 ± 5 5.00 ± 5 4.90 ± 4
Plasma Selenoprotein P AUC (mgh/L)
Day 1 93.4 ± 11 84.1 ± 9 87.8 ± 16 77.9 ± 12 87.5 ± 11
Day 84 93.9 ± 23 87.1 ± 9 88.7 ± 13 74.3 ± 11 89.6 ± 10
1Change from day 1 to day 84 p < .05 (paired t test).
*Mean ± SD.
Table 3: Plasma selenium pharmacokinetics
Treatment Group
Agent Placebo Methyl Selenocysteine Selenomethionine
Dose   400 mcg 800 mcg  400 mcg 800 mcg
N 3 7 5 5 5
Plasma Se Cmax (mcg/L)
Day 1 110 ± 9 122 ± 13 131 ± 10 126 ± 12 137 ± 16
Day 84 106 ± 18 136 ± 121 143 ± 18 252 ± 311 319 ± 391
Plasma Se Tmax (hr)
Day 1 3.67 ± 4 6.43 ± 9 3.50 ± 3 9.20 ± 9 7.40 ± 4
Day 84 2.33 ± 1 3.29 ± 3 2.50 ± 2 3.50 ± 5 2.70 ± 3
Plasma Se AUC (mcgh/L)
Day 1 1170 ± 44 1330 ± 138 1410 ± 132 1370 ± 84 1480 ± 194
Day 84 1160 ± 102 1490 ± 1111 1530 ± 183 2780 ± 3561 3420 ± 5151
1Change from day 1 to day 84 p < .05 (paired t test).
*Mean ± SD.
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baseline selenium status [14], the median baseline serum 
selenium concentration of those participants was 135 
mcg/L, and only 20% of subjects had serum levels below 
121.6 mcg/L [10]. (Serum selenium concentrations 
approximate those in plasma.) In NPC, the mean baseline 
plasma selenium was 115 mcg/L, and the upper boundary 
of the lowest tertile was 105 mcg/L. Part of the rationale 
for the NPC trial was suspected selenium deficiency [9]: 
selenium status is optimized at a blood level of 85 mcg/L 
[29]. It is unlikely that more than a small fraction of the 
participants in SELECT, including those in the lowest 
percentiles, were at levels in which their selenium status 
was not optimized. In NPC, some 20 % of subjects had 
baseline plasma levels below 85 mcg/L (unpublished NPC 
data). The SEPP1 concentrations and GPX activity levels 
of subjects in the present trial, whose average baseline 
plasma selenium concentration was approximately 
108 mcg/L—much lower than that of subjects in SELECT, 
but higher than that of many subjects in NPC—were not 
affected statistically significantly, or substantially, by 
supplementation. With plasma in the human optimized at a 
plasma concentration of approximately 85 mcg/L,selenium 
above 85 mcg/L is mainly stored in albumin as SEMET 
[29]. In a subject with a plasma concentration of 108 
mcg/L, approximately 85 mcg/L would be selenoproteins, 
and 23 mcg/L would be SEMET. This study was not able 
to measure SEMET in plasma. It is possible, however, 
that, for some trial participants, selenoproteins were below 
85 mcg/L. The modest, statistically insignificant increases 
observed in SEPP1 may indicate that some subjects were 
Table 5: Plasma Gpx pharmacokinetics
Treatment Group
Agent Placebo Methyl Selenocysteine Selenomethionine
Dose   400 mcg 800 mcg  400 mcg 800 mcg
N 3 7 5 5 5
Plasma Glutathione Peroxidase Cmax (Units/L)
Day 1 202 ± 137 138 ± 23.3 188 ± 49.5 144 ± 30.9 220 ± 116
Day 84 145 ± 71 142 ± 23.3 219 ± 45.7 144 ± 30.2 206 ± 70.2 
Plasma Glutathione Peroxidase Tmax (hr)
Day 1 3.33 ± 4.16 4.36 ± 3.77 6.60 ± 10.0 4.00 ± 3.10 6.10 ± 10.0
Day 84 2.00 ± 1.80 2.50 ± 2.16 3.60 ± 4.94 3.20 ± 3.83 6.20 ± 2.86
Plasma Glutathione Peroxidase AUC (Unitshr/L)
Day 1 1560 ± 718 1390 ± 218 1680 ± 372 1370 ± 191 1630 ± 301
Day 84 1430 ± 593 1430 ± 279 1900 ± 166 1430 ± 251 1950 ± 442 
*Mean ± SD.
Table 6: Urinary selenium excretion (mcg), day and treatment group
Treatment Group
Placebo Methyl Selenocystene Selenomethionine
Day 1 400 mcg 800 mcg 400 mcg 800 mcg
Total (0–12 hrs) 27.4 ± 7 67.2 ± 18 147 ± 98 103 ± 38 155 ± 31
Ratio; 0-12 hrs
Excretion/dose N/A .17 .28 .26 .19
Day 84
Total (0–12 hrs) 26.0 ± 9 168 ± 451 256 ± 71 156 ± 591 237 ± 54
Ratio; Excretion/dose N/A .42 .32 .39 .30
*Mean ± SD.
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marginally deficient in selenoproteins. An effect involving 
supplication’s modification of histone acetylation and 
deacetylation on carcinogenesis would not necessarily be 
dependent on baseline selenium levels [31, 32]. Given that 
the biology of organoselenium compounds is complex and 
is as yet incompletely understood, other biomarkers that 
provide more insight are needed. 
In light of interest in Se as a possible 
chemopreventive agent, this study sought as a first goal 
to assess toxicity. There was no evidence of toxicity. 
Preclinical toxicology studies of MSC—long and short 
term— were performed by the National Cancer Institute, 
through the Division of Cancer Prevention (DCP) 
Rapid Access to Preventive Intervention Development 
(RAPID) Program [43, 44]. The studies, conducted in 
the expectation of chemoprevention based on selenium 
supplementation, provided little evidence of toxicity at 
doses well in excess of usual human intake. These findings, 
providing no evidence of toxicity with treatment by up to 
800 mcg/day for 84 days, are consistent with the RAPID 
results [13, 29].
Selenium is a natural dietary constituent, so that 
varying baseline concentrations were present in the 
plasma of subjects. In order to accurately gauge the 
pharmacokinetic parameters, the analyses took these 
baseline values into consideration by focusing on changes 
in means. Supplementation of individuals with plasma 
selenium above 85 mcg/L will increasingly be excreted, 
rather than converted into selenoproteins. Although this 
study did not collect breath or fecal samples, it can be 
safely assumed that substantial amounts of the selenium 
supplements ingested were excreted in breath or feces [29]. 
The findings of this study, in keeping with those 
of other studies, confirm that selenium supplementation 
by SEMET leads to selenium accumulation in blood, 
as selenomethionine is incorporated into proteins 
at methionine positions; supplementation by MSC 
does not lead to accumulation in proteins. Selenium 
supplementation did not substantially affect the 
generation of the major selenoproteins, SEPP1 or GPX, 
because the subjects were not selenium deficient [29]. 
That these subjects were close to being selenium replete 
is substantiated by the substantial increases in urinary 
selenium excretion engendered by SEMET and MSC. 
The findings are consistent with the passive 
movement of SEMET into a large storage reservoir. 
Figure 1: Phase 1 Multiple Dose Study of 12-week treatment by Se=Methyl-L-Selenocysteine (MSC) and 
L-Selenomethionine (SEMET) in adult males.
Oncotarget26319www.impactjournals.com/oncotarget
As SEMET accumulates within proteins, with SEMET 
substituting for methionine, the body provides an 
unregulated pool. In one previous study, SEMET 
supplementation for one month by 400 mcg/day of 
selenium caused the ratio of SEMET to methionine 
in albumin to increase from 1/8000 to 1/2800 [29]. 
Nonetheless, intake of selenium in an individual whose 
selenoproteins are optimized will lead not to the formation 
of selenoproteins but to selenium excretion; the liver will 
package selenium as methyl selenol, dimethyl selenide, 
trimethyl selenonium and selenosugar, and excrete it. 
Preclinical, cell-line data indicated that MSC 
provides a more efficient route than SeMet to the 
formation of methyl selenol, a metabolite that in cell 
lines imparts a chemopreventive effect [23, 27, 41, 45]. 
However, methyl selenol may, in vivo, be merely a first 
step on an excretory pathway [29]. It may be important in 
the future to accurately speciate methyl selenol and related 
plasma selenium metabolites in vivo; this may be key to 
the role of selenium in cancer risk. The major downstream 
protein products of selenium supplementation, SEPP1 and 
GPX, which are the key and most abundant selenoproteins 
in plasma, can be readily evaluated. This research has 
emphasized two selenoproteins to which selenium gives 
rise [13, 46]. The search for other supplementation 
biomarkers, however, should not be overlooked.
Ip and others, in research based largely on cell-
line analysis, suggested that MSC would be more 
physiologically relevant to chemoprevention than SEMET 
or other selenocompounds. It has efficacy in the preclinical 
models Ip and colleagues studied, and it was therefore 
hypothesized to represent an important potentially 
chemopreventive agent [15, 23, 24, 27, 28, 35, 37, 45]. 
These findings provide little evidence that either form is 
pertinent to the formation of selenoproteins in individuals 
who are selenium replete. If either of these agents is 
active, that action is not seen through the formation of the 
primary plasma selenoproteins.
The SELECT results leave little room for hope that 
selenium supplementation, with selenium in the form 
of SEMET, has chemopreventive efficacy for selenium-
replete subjects [10]. Whether supplementation will be 
of benefit to those who are not selenium replete is less 
clear; the results reported by the Clark trial suggest that it 
may be [5–8]. Research on the impact of supplementation 
to cancer risk will have to be conducted in populations 
in which selenium deficiency is much more common 
than in most of the United States. The findings of this 
study explain little regarding the discrepant findings of 
NPC, SELECT and SWOG 9917; the most plausible 
explanation is that, if selenium has preventive value, 
it must either be for individuals whose selenium status 
is less than optimal, or by means of MSC or another 
formulation of selenium. 
MATERIALS AND METHODS
Participants
An IRB approved, Phase I multiple-dose, dose-
escalation pharmacokinetic/toxicity study of SEMET and 
MSC was conducted at Roswell Park Cancer Institute 
(RPCI). Healthy male volunteers were recruited as 
subjects by public announcement in Buffalo, NY. After 
granting informed consent verbally and in writing, 
subjects were randomized, double-blinded, to receive daily 
doses of either MSC or SEMET, either 400 or 800 mcg Se/
day, or placebo, for 84 days. In the first wave, 5 patients 
were assigned to 400 mcg of selenium as MSC, 5 to the 
same selenium dose as SEMET and two to placebo; in the 
second wave, 5 patients were assigned to receive 800 mcg 
of selenium as MSC, five to the same selenium dose as 
SEMET, and two to placebo.  The goal of placebo-group 
inclusion was to decrease the likelihood of confounding 
by participant reporting of inconsequential, subjective 
symptoms of toxicity. The placebo arm is displayed in 
the results, although the placebo data are not included in 
statistical analyses. With a total of only 3 placebo patients, 
and only 5–7 patients in each selenium-supplementation 
group, precision of comparisons to placebo patients is 
extremely limited the treatment groups—400 mcg Se as 
MSC; 400 mcg Se as SEMET; 800 mcg Se as MSC; 800 
mcg Se as SEMET—will be referenced as 400 or 800 
mcg: these refer to the amount of selenium, rather than to 
the amount of SEMET or MSC, in the doses.
Subjects were required to have normal hepatic, 
renal and bone marrow function as assessed by history, 
physical, and clinical chemistry analysis. They could not 
have donated blood within 30 days of first blood sampling, 
had to be 18 or older, to have an Eastern Cooperative 
Oncology Group (ECOG) performance status [47] of 
0 or 1, and to weigh between 50 and 115 kg. Eligibility 
was restricted to males, because the most convincing 
association of selenium supplementation with reduced risk 
in the NPC study was seen with prostate cancer. Subjects 
could not be taking prescription or nonprescription drugs, 
vitamins or herbal supplements known to affect gastric 
acidity within three days of agent administration.  
Pharmacokinetic analysis was undertaken on days 1 
and 84. Subjects arrived at RPCI at 7:00 am on days 1 and 
84 after a fast that began at 10:00 pm the previous night. 
After a brief review of concurrent medications and vital 
signs and symptoms, subjects had an intravenous catheter 
placed in one arm. A baseline pre-dose blood sample was 
drawn through the catheter, after which subjects ingested 
the assigned agent along with 8 ounces of water under 
direct supervision. Subjects remained in hospital for 
12 hours, returning at 24 hours. Blood was drawn previous 
to dosing at baseline and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 
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8.0, 10.0, 12.0 and 24 hours after the first day’s dosing. A 
predose blood sample was collected on day 28. On day 84, 
blood was drawn as on day 1 up to 12 hours after dosing. 
Each sample was treated with 1 mg of disodium EDTA 
per ml to prevent coagulation. Plasma was obtained by 
centrifugation. Urine output was collected within time 
spans of 0–4, 4–8 and 8–12 hours. Figure 1 summarizes 
this schema. All participants in the 400 mcg groups were 
treated and evaluated for toxicity prior to treating those in 
the 800 mcg groups. The occurrence of grade 2 or greater 
toxicity thought at least possibly due to agent was set to 
preclude escalation to the next higher dose.
Plasma and urine selenium concentrations and 
plasma SEPP1 concentration and GPX activity were 
determined by the methods of Burk et al [13]. Selenium in 
urine was measured by the ratio of selenium to creatinine, 
and by urinary excretion of selenium.
Methods/statistics
Toxicity was evaluated in all subjects. History 
was reviewed at baseline; physical examinations were 
conducted at screening, on days 1, 28 and 84. Medications 
were reviewed at screening, days 1, 2, 3, 28 and 84. 
Participants were contacted by telephone for weight 
change and gastrointestinal distress, with all toxicities 
recorded, on days 14, 45, 60 and 112. Vital signs were 
checked at screening, day 1, 2, 3, 28, and 84. Clinical 
laboratory studies, including SGOT/SGPT, total bilirubin, 
serum electrolytes with BUN, TSH, T4 and creatinine, 
fasting blood sugar, lipid panel (total cholesterol, HDL, 
LDL, triglycerides), PSA and urinalysis, were performed 
at screening, day 1, day 28 and day 84. Participants were 
contacted by telephone 30 days after their participation 
was complete for toxicity assessment. Toxicities for all 
consented subjects were recorded and graded according to 
the National Cancer Institute Common Toxicity Criteria 
(CTC) version 3.0 [47].
Quantitative descriptors of subjects—age, 
baseline plasma selenium, height, weight and ECOG 
[47] performance status—were compared by means 
and standard deviations. One-way analysis of variance 
(ANOVA) was used to identify the statistical significance 
of variance among the group means. These comparisons 
do not include the placebo group. Because the focus of this 
trial was on changes in biomarkers, statistical significance 
emphasized changes in means, tested by paired t tests. As 
the statistical power of comparisons was limited by the 
small number of patients in any one group, interpretation 
of the findings is necessarily conservative. The .05 level 
of statistical significance was used, and all analyses were 
two-tailed.
CONCLUSIONS
This study confirms that, for men with adequate 
selenium nutriture, as indicated by plasma selenium 
concentrations in the vicinity of 108 mcg/L, 12 week 
supplementation by 400 and 800 mcg of selenium, whether 
by MSC or SEMET, does not lead to toxicity. MSC and 
SEMET demonstrate differential pharmacokinetics. 
Neither form, however, has any impact on the formation 
of the major selenoproteins: SEPP1 and GPX. If selenium 
supplementation has any chemopreventive activity among 
selenium replete subjects, it is probably by mechanisms 
other than the formation of these two selenoproteins. 
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